Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of March 31, 2017 and December 31, 2016:

	March 31, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	49,600	$	49,600
August 2014 Warrants		—		160,000		—		160,000
Total	$	—	$	160,000	$	49,600	$	209,600

	December 31, 2016
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	27,125	$	27,125
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	27,125	$	127,125

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	Three Months		Twelve Months
	Ended		Ended
	March 31,		December 31,
	2017		2016
Beginning balance – Fair value	$	27,125	$	2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities		—		(1,392,429)
Loss (gain) on derivatives resulting from change in fair value or extinguishment		22,475		(647,446)
Ending balance – Fair value	$	49,600	$	27,125

2013 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used:

	Three Months			Twelve Months
	Ended			Ended
	March 31,			December 31,
	2017			2016
Volatility		118	%		92.72-134	%
Risk-free interest rate		1.03	%		0.53-1.15	%
Expected life (years)		0.89			1.14-1.89
Dividend		0	%		0	%

2015 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments:

	Twelve Months
	Ended
	December 31,
	2016
Volatility		89.73	%
Risk-free interest rate		1.65	%
Expected life (years)		4.50
Dividend		0	%